Palabras clave
Psiquiatría Infantil
Psiquiatría del Adolescente
Cómo citar
Resumen
La reciente creación de la especialidad de Psiquiatría de la Infancia y la Adolescencia responde a un aumento creciente en cuanto a conocimientos sobre la salud mental infantojuvenil, y también al ascenso significativo de la prevalencia de diferentes trastornos y patologías psiquiátricas en este grupo de edad.
Por ello, a continuación se desarrolla una revisión sobre conceptos básicos acerca de neurotransmisión y psicofármacos más frecuentemente utilizados, describiendo su potencial uso, efectos adversos más frecuentes, consideraciones y conclusiones al respecto.
Con este texto, se pretende permitir a los pediatras tanto de atención primaria como de ámbito hospitalario emplear este tipo de medicaciones, aportando una evidencia sólida y una mayor seguridad en cuanto a la asistencia a pacientes psiquiátricos.
Referencias
Casey BJ, Jones RM, Hare TA. The adolescent brain. Ann N Y Acad Sci. 2008;1124:111-26. https://doi.org/10.1196/ annals.1440.010
https://doi.org/10.1196/annals.1440.010
Paus T, Keshavan M, Giedd JN. Why do many psychiatric disorders emerge during adolescence? Nat Rev Neurosci. 2008; 9(12):947-57. https://doi.org/10.1038/nrn2513
https://doi.org/10.1038/nrn2513
Kandel ER, et al. Principles of Neural Science. McGraw-Hill.
Grace AA. Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression. Nat Rev Neurosci. 2016;17(8):524-32. https://doi.org/10.1038/nrn.2016.57
https://doi.org/10.1038/nrn.2016.57
Stahl SM, Morrissette DA, Citrome L, Saklad SR, Cummings MA, Meyer JM, et al. "Meta-guidelines" for the management of patients with schizophrenia. CNS Spectr. 2013;18(3):150-62. https://doi.org/10.1017/S109285291300014X
https://doi.org/10.1017/S109285291300014X
Arnsten AF. The emerging neurobiology of attention deficit hyperactivity disorder: The key role of the prefrontal association cortex. J Pediatr. 2009;154(5):I-S43. https://doi.org/10.1016/j. jpeds.2009.01.018
Cowen PJ, Browning M. What has serotonin to do with depression? World Psychiatry. 2015;14(2):158-60. https://doi. org/10.1002/wps.20229
https://doi.org/10.1002/wps.20229
Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, et al. Clinical response and risk for reported suicidal idea- tion and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007; 297(15):1683-96. https://doi.org/10.1001/jama.297.15.1683
https://doi.org/10.1001/jama.297.15.1683
Möhler H. The GABA system in anxiety and depression and its therapeutic potential. Neuropharmacology. 2012;62(1):42-53. https://doi.org/10.1016/j.neuropharm.2011.08.040
Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev. 2010;62(3):405-96. https://doi.org/10.1124/pr.109.002451
Daly EJ, Singh JB, Fedgchin M, Kimberly Cooper K, Lim P, Shelton RC, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2018;75(2):139-48. https://doi.org/10.1001/jamapsychiatry.2017.3739
Deepmala, Slattery J, Kumar N, Delhey L, Berk M, Dean O, et al. Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review. Neurosci Biobehav Rev. 2015;55:294-321. https://doi.org/10.1016/j.neubiorev.2015.04.015
Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16(1):22-34. https://doi.org/10.1038/nri.2015.5
Selemon LD. A role for synaptic plasticity in the adolescent development of executive function. Transl Psychiatry. 2013;3:e238. https://doi.org/10.1038/tp.2013.7
Hicks JK, Bishop JR, Sangkuhl K, Müller DJ, Ji Y, Leckband SG, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015;98(2):127-34. https://doi.org/10.1002/cpt.147
Seeman P. Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses. 2010;4(1):56-73.
https://doi.org/10.3371/CSRP.4.1.5
Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull. 2009;35(3):549-62. https://doi.org/10.1093/schbul/sbp006
Correll CU. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry. 2008;47(1):9-20. https://doi.org/10.1097/ chi.0b013e31815b5cb1
De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8(2):114-26. https://doi. org/10.1038/nrendo.2011.156
Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765-73. https://doi. org/10.1001/jama.2009.1549
Strawn JR, Keck PE, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007;164(6):870-6. https://doi. org/10.1176/ajp.2007.164.6.870
Cipriani A, Zhou X, Del Giovane C, Hetrick SE, Qin B, Whitting- ton C, et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet. 2016;388(10047):881-90. https://doi.org/10.1016/S0140-6736(16)30385-3
Harmer CJ, Duman RS, Cowen PJ. How do antidepressants work? New perspectives for refining future treatment approaches. Lancet Psychiatry. 2017;4(5):409-418. https://doi.org/10.1016/ S2215-0366(17)30015-9
Ferguson JM. SSRI antidepressant medications: Adverse effects and tolerability. Prim Care Companion J Clin Psychiatry. 2001;3(1):22-7. https://doi.org/10.4088/pcc.v03n0105
Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007; 297(15):1683-96. https://doi.org/10.1001/jama.297.15.1683
Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-20. https://doi.org/10.1056/ NEJMra041867
Rudolph U, Möhler H. GABA-based therapeutic approaches: GABAA receptor subtype functions. Curr Opin Pharmacol. 2006;6(1):18-23. https://doi.org/10.1016/j.coph.2005.10.003
Baldwin DS, Aitchison K, Bateson A, Curran HV, Davies S, Leonard B, et al. Benzodiazepines: risks and benefits. A reconsideration. J Psychopharmacol. 2013;27(11):967-71. https:// doi.org/10.1177/0269881113503509
Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiatry. 2015;72(2):136-42. https:// doi.org/10.1001/jamapsychiatry.2014.1763
Hoffman EJ, Warren EW. Flumazenil: a benzodiazepine antagonist. Clin Pharm. 1993;12(9):641-56.
Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci. 2004;5(7):553-64. https://doi.org/ 10.1038/nrn1430
Perucca E. Current trends in antiepileptic drug therapy. Epilepsia. 2003;44 Suppl 4:41-7. https://doi.org/10.1046/ j.1528-1157.44.s4.1.x
Mula M, Sander JW. Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf. 2007;30(7):555-67. https://doi.org/10.2165/00002018-200730070-00001
Malhi GS, Tanious M, Das P, Coulston CM, Berk M. Potential mechanisms of action of lithium in bipolar disorder: current understanding. CNS Drugs. 2013;27(2):135-53. https://doi.org/10.1007/s40263-013-0039-0
Faraone SV, Biederman J, Spencer TJ, Aleardi M. Comparing the efficacy of medications for ADHD using meta-analysis. Med Gen Med. 2006;8(4):4.
Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, et al. Review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry. 2013;54(3):227-46. https://doi.org/10.1111/jcpp.12036
Coghill DR, Caballero B, Sorooshian S, Civil R. A systematic review of the safety of lisdexamfetamine dimesylate. CNS Drugs. 2014;28(6):497-511. https://doi.org/10.1007/s40263-014- 0166-2
Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108(5):E83. https://doi.org/10.1542/peds.108.5.e83
Sallee FR, McGough J, Wigal T, Donahue J, Lyne A, Bieder- man J; SPD503 Study Group. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48(2):155-65. https://doi.org/10.1097/ CHI.0b013e318191769e
Wilens TE, Spencer TJ, Biederman J, Girard K, Doyle R, Prin- ce J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry. 2001;158(2):282-8. https://doi.org/10.1176/appi. ajp.158.2.282.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Derechos de autor 2026 Boletín de Pediatría